Simplicity Solutions’s Carisma Therapeutics CARM Stock Holding History

Simplicity Solutions’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$10K	–	676
2019 Q1	$10K	Buy	+500	New	+$8.63K	﹤0.01%	746

Other funds holding CARM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Simplicity Solutions's CARM Position: Q2 2019 in Review

Simplicity Solutions sold out of Carisma Therapeutics (CARM) in Q2 2019, closing a stake of 500 shares — an estimated $10K sold.

Simplicity Solutions first reported a position in CARM in Q1 2019 and held it in 1 quarter. The position peaked at $10K in Q1 2019. 43 funds tracked by Wall St. Rank hold CARM as of Q2 2019.

Simplicity Solutions reported no remaining Carisma Therapeutics position as of Q2 2019 after selling out during the quarter.
Simplicity Solutions sold 500 Carisma Therapeutics shares in Q2 2019, an estimated $10K.
Simplicity Solutions first reported a position in Carisma Therapeutics in Q1 2019 and held it in 1 quarter.
Simplicity Solutions's Carisma Therapeutics position peaked at $10K in Q1 2019.
43 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2019.

Based on Simplicity Solutions's 13F filing for Q2 2019, filed 8 Aug 2019.